Female kidney cancer patients undergoing surgery for non-metastatic disease may have more favourable prognosis

A retrospective analysis of over 2000 patients from the International Marker Consortium for Renal Cancer (INMARC) database showed that female patients with non-metastatic clear cell renal cell carcinoma (ccRCC) had lower grade, lower stage, and longer relapse-free survival after partial or radical nephrectomy for their cancer. In conclusion, this study suggests that female patients with […]

read more

ASCO GU 2020: Nephrectomy linked to longer overall survival in patients treated with immunotherapy or targeted therapy for advanced kidney cancer

Surgery to remove the kidney tumour is often the preferred treatment for people with kidney cancer that has not spread. Recently, doctors have been questioning whether it is beneficial to operate to remove the kidney tumour in patients with kidney cancer that has already spread beyond the kidney. Immunotherapies for advanced kidney cancer include drugs […]

read more

Nephrectomy after complete response to immunotherapy

A retrospective study looked at the clinical and surgical outcomes in 11 patients with metastatic clear cell renal cell carcinoma (RCC) who had a delayed nephrectomy following a complete response to immunotherapy or immunotherapy and targeted therapy combinations. There were surgical difficulties in 81.8% of cases caused by adhesions and inflammatory reactions. At 15 months […]

read more

Effect of obesity and being overweight on complications and survival after surgery in kidney cancer patients

A recent study published in the Journal of Endourology this month shows that obese and overweight patients do not experience higher complication rates or worse kidney function after key-hole (laparoscopic) surgery for stage 2 kidney cancer. This surgery can, therefore, be deemed feasible and safe in this group of patients. Nevertheless, obese and overweight patients […]

read more

Renal function after surgery for kidney cancer may impact cancer-specific survival

The results from a single-centre study reported in Clinical Genitourinary Cancer recently found that partial nephrectomy (nephron-sparing surgery) for localised renal cell carcinoma (RCC) may decrease the risk of cancer-specific mortality in some patients. The study was conducted in 1767 patients who underwent either partial or radical nephrectomy for RCC at the University of Brescia […]

read more

Percutaneous ablation for small renal masses

Current guidelines recommend partial nephrectomy as the preferred treatment option for small renal masses. Percutaneous ablation, such as radiofrequency ablation and cryoablation, are mainly considered for patients who are not suitable for surgery or who have other conditions (co-morbidities) that make them unfit for surgery. There is currently a lack of evidence comparing partial nephrectomy […]

read more

Long term survival after radiofrequency ablation for kidney cancer

A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC). The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were […]

read more

Renal mass biopsy in the management of kidney cancer

A review of the evolving field of the management of renal masses has been published in the Canadian Urological Association Journal. In this review, an expert panel from the Kidney Cancer Research Network of Canada provided the following recommendations: Renal mass biopsy should be offered to patients if the results of the biopsy will change […]

read more

Radiofrequency ablation and systemic treatment for kidney cancer lung metastases

A recent study published in BMC Cancer reports on the safety and efficacy of radiofrequency ablation (RFA) for local treatment of renal cell carcinoma (RCC) lung metastases in combination with systemic treatments. The researchers treated 100 lung metastases in 53 patients with RFA. Median follow-up time was 61 months and 5-year overall survival was 62%. Median […]

read more

The case for SBRT as kidney cancer treatment

In this video interview, Dr Vitaly Margulis, from the University of Texas Southwestern Medical Center in Dallas, outlines the advantages of stereotactic body radiation therapy (SBRT) and talks about the forthcoming RADVAX clinical trial in the USA, which combines radiotherapy and immunotherapy. Oncologists are often taught that renal cell carcinoma (RCC) is resistant to radiotherapy. […]

read more
Showing 1 to 10 of 58 results
  TOP